Abstract
Based on the superior response rates (21% to 24%) of patients treated with single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in Eastern Cooperative Oncology Group and M.D. Anderson Cancer Center trials in non-small cell lung cancer (NSCLC) and on the superior 1-year survival rates of NSCLC patients treated with carboplatin in a randomized study of cisplatin combination and analogues, we initiated a phase II trial of paclitaxel/carboplatin in patients with stage IV or effusion-positive stage III NSCLC. Eligibility stipulated chemotherapy-naive patients with measurable disease, good performance status, and adequate hematologic, hepatic, and renal function. Previous radiotherapy was restricted to < or = 30% of marrow-bearing bone. Paclitaxel was initially given at 135 mg/m2 over 24 hours followed by carboplatin dosed to a targeted area under the concentration versus time curve (AUC) of 7.5, with treatment repeated at 3-week intervals for six cycles. Granulocyte colony-stimulating factor was introduced during the second and subsequent cycles, with the paclitaxel dose sequentially escalated in 40 mg/m2 increments to a maximum dose of 215 mg/m2 in patients with less than grade 4 granulocytopenia and less th...Continue Reading
Citations
Mar 21, 1998·Radiation Oncology Investigations·L PlasswilmR Sauer
Feb 10, 1998·The Annals of Thoracic Surgery·L H Einhorn
Jun 23, 2000·International Journal of Radiation Oncology, Biology, Physics·H ChoyD H Johnson
Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A L ThomasK J O'Byrne
Apr 6, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E LaackD K Hossfeld
Mar 31, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C J LangerR F Ozols
Dec 12, 2001·Critical Reviews in Oncology/hematology·M S AaproJ B Vermorken
Mar 6, 1999·Journal of the American College of Nutrition·K N PrasadW C Cole
Oct 8, 1999·Journal of the American College of Nutrition·K N PrasadB Kumar
Jan 5, 2002·Journal of the American College of Nutrition·B KumarK N Prasad
Oct 18, 2001·Journal of the American College of Nutrition·K N PrasadK C Prasad
Dec 14, 2002·Journal of the American College of Nutrition·Kedar N PrasadK Che Prasad
Mar 4, 2010·Journal of Pharmaceutical Sciences·Adam W G AlaniGlen S Kwon
May 27, 2008·Clinical Lung Cancer·Robert A SomerCorey J Langer